IGC Pharma, Inc.

Overview

Compare with Vistagen Therapeutics, Inc., SciSparc or NRX Pharmaceuticals, Inc., or pick any stock.

• TickerIGC on NYSE¹
• IndustryPharmaceutical Preparations¹
• HeadquartersPotomac, Maryland¹
• Incorporated inMD³
• Business address10224 Falls Road, Potomac, Md 20854³
• Filer categoryNon-accelerated filer, Smaller reporting company³

See how the biggest companies compare on our leaderboards

Operations” and Item 8 of this Annual Report on Form 10-K, for further information on business segments.⁴ From its latest annual report

Corporate structure

IGC Pharma, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What IGC Pharma, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Intangibles and goodwill

Inventory

Properties, in its own words

Our corporate headquarters is located in Potomac, Maryland. We own approximately 40,000 square feet of property used for general management and R&D operations. In addition, we have leases in the U.S. and internationally that are used for sales, storage, accounting, management, and R&D. During the Transition Period, the Company discontinued its leased facility in Vancouver, Washington, and no longer maintains a direct operating presence at that location. The Company believes its existing facilities, which are used by all reportable segments, are in good operating condition and suitable for conducting its business.

Please refer to Note 6 – “Property, Plant and Equipment”, and Note 7 – “Dispositions and Disposals”, for more information on Part II, Item 8.

Item 2 of the 10-KT filed Mar 18, 2026.¹⁵

Leadership

Who has led IGC Pharma, Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerRam Mukunda Mar 15, 2006 to now¹⁶
• ChairRam Mukunda May 18, 2009 to Mar 8, 2021¹⁷
• PresidentRam Mukunda Mar 15, 2006 to Mar 15, 2006¹⁶
• Chief financial officerJohn Cherin Feb 27, 2017 to Sep 14, 2017¹⁸
• Chief financial officerShu Kwong Ngai Aug 26, 2013 to Aug 26, 2013¹⁹

Former names

• India Globalization Capital, Inc.May 13, 2005 to Mar 21, 2023³

Timeline

1. Jul 14, 20268-K Regulation FD disclosure³¹
2. Jul 6, 20268-K Entered a material agreement; Unregistered sale of shares³²
3. Jun 8, 20268-K Entered a material agreement; New debt or obligation³³
4. Apr 20, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁴
5. Mar 30, 20268-K Other events³⁵
6. Mar 12, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares³⁶
7. Jan 6, 20268-K Entered a material agreement³⁷
8. Jan 2, 20268-K Bylaws or fiscal year changed³⁸
9. Dec 15, 20258-K Bylaws or fiscal year changed³⁹
10. Nov 14, 20258-K Completed an acquisition or sale⁴⁰
11. Oct 14, 20258-K Shareholder vote; Other events⁴¹
12. Oct 1, 20258-K Entered a material agreement⁴²
13. Mar 15, 2006New chief executive Ram Mukunda becomes CEO¹⁶

Calendar

Coming up

1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.02) a share, on Nov 14, 2025.⁴³

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

141 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 37 major events, 43 insider forms, 2 large holders, 39 other. The latest 20:

1. Sep 29, 20264 EDGAR
2. Sep 29, 20264 EDGAR
3. Aug 14, 202610-Q EDGAR
4. Jul 14, 20268-K EDGAR
5. Jul 6, 20268-K EDGAR
6. Jul 1, 20264 EDGAR
7. Jul 1, 20264 EDGAR
8. Jun 8, 20268-K EDGAR
9. May 15, 202610-Q EDGAR
10. Apr 20, 20268-K EDGAR
11. Apr 6, 20264 EDGAR
12. Apr 6, 20264 EDGAR
13. Apr 6, 20264 EDGAR
14. Apr 6, 20264 EDGAR
15. Mar 30, 20268-K EDGAR
16. Mar 18, 202610-KT EDGAR
17. Mar 12, 20268-K EDGAR
18. Feb 4, 20264 EDGAR
19. Jan 20, 20264 EDGAR
20. Jan 6, 20268-K EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 1 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Bradbury Strategic Investment Fund A (Cayman Islands Registration No. CR-359857)SC 13D/A, 2 filings May 21, 2024 to Aug 14, 2024⁴⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 36. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How IGC Pharma, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARIGC Pharma, Inc.¹
• CIK0001326205
• Employer ID (EIN)20-2760393¹⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company¹⁵
• Incorporated inMaryland¹⁵
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address10224 Falls Road, Potomac, MD 20854¹
• Phone301-529-4996¹
• Shares outstanding103,384,008 as of Aug 5, 2026¹³
• Public float$18.5M as of Jun 30, 2025¹⁵
• AuditorManohar Chowdhry & Associates, Chennai, India PCAOB ID 5341; no auditor attestation of internal control over financial reporting¹⁵
• On EDGAR sinceMay 13, 2005¹
• Filings815 in all: 8-K (186), 4 (112), CORRESP (67), 10-Q (55), UPLOAD (47), SC 13G/A (36), NT 10-Q (21), SC 13G (21)¹
  All 53 form types

  424B5 (20), 3 (18), DEF 14A (18), EFFECT (18), 10-K (17), 5 (17), S-1/A (17), NT 10-K (13), S-3 (13), S-3/A (12), POS AM (10), PRE 14A (8), 144 (7), S-8 (7), 10QSB (6), 5/A (5), 8-K/A (5), DEFA14A (5), SC 13D (5), 10-K/A (4), 424B3 (4), SC 13D/A (4), SC TO-I/A (4), 10KSB (3), 4/A (3), 424B4 (3), PRER14A (3), S-1 (3), 10KSB/A (2), 10-KT (1), 10-Q/A (1), 25 (1), 25-NSE (1), 3/A (1), 8-A12B (1), 8-A12G (1), 8-A12G/A (1), ARS (1), AW (1), CERTAMX (1), DEFR14A (1), NT 10-Q/A (1), PREM14A (1), REGDEX (1), SC TO-I (1)

• Latest filingsAnnual report (10-KT) Mar 18, 2026
  Quarterly report (10-Q) Aug 14, 2026
  Proxy statement (DEF 14A) Aug 18, 2025
  Latest 8-K (8-K) Jul 14, 2026

Securities registered for trading

From the cover page of the 10-KT filed Mar 18, 2026 (Section 12(b) of the Exchange Act).¹⁵

Risk factors and legal proceedings

The risks IGC Pharma, Inc. names in Item 1A of its 10-KT filed Mar 18, 2026: 41 risks under these headings, as written.¹⁵

• We have limited revenues, incurred significant losses, and have an accumulated deficit. If we cannot achieve profitability, the market price of our common stock could decline significantly.
• We may be unable to complete financings on acceptable terms, certain financings are subject to required approvals, and we have sought and may continue to seek financing from our officers and directors.
• We Depend on a Limited Number of Customers for a Significant Portion of Our Life Sciences Revenue.
• Our classification as a “cannabis company” creates institutional barriers to capital that may require us to utilize higher-cost alternative financing.
• We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management, which ultimately may not be successful.
• Global Operations
• Legal claims could be filed that may have a material adverse effect on our business, operating results, and financial condition. We may, in the future, face risks of litigation and liability claims. The extent of such exposure can be difficult or impossible to estimate, which can negatively impact our financial condition and results of operations.
• Our Company is in a highly regulated industry. Significant and unforeseen changes in policy may have material impacts on our business.
• Our Company is inexperienced in conducting pre-clinical and clinical trials.
• Clinical trials are expensive, time-consuming, and difficult to design and implement, and involve an uncertain outcome.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming, and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for IGC-AD1 or any other product candidates, our business will be substantially harmed.
• We have concentrated our research and development efforts on the treatment of Alzheimer’s Disease, which has seen limited success in drug development. Further, IGC-AD1 is based on a new approach to treating symptoms of Alzheimer’s Disease, which makes it difficult to predict the time and cost of development and subsequent obtaining of regulatory approval.

Legal proceedings

The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

As of December 31, 2025, the following material litigation is pending:

Engineering and Consulting Group SAS et al. v IGC Pharma Inc., case file no. 110016000050202247710 (Prosecutor’s Office 393 Sectional Economic Crimes Unit, Bogota, Colombia). The Company and the ECG corporation are in a contractual dispute. The Company filed a complaint against four (4) individuals with the Prosecutor’s Office 393 Sectional Economic Crimes Unit, Bogota, Colombia, under file no. 110016000050202247710 for charges of fraud, falsification of a private document, and conspiracy to commit a crime. The complaint was filed in 2022. In December 2023, the case was reviewed by the investigator and scheduled and accepted for a hearing by the prosecutor in calendar 2024. During the nine months ended December 31, 2025, the Company met with the prosecutors and pressed the urgency of moving the case through the legal system.

The opening of Item 3, Legal Proceedings.¹⁵